<DOC>
	<DOCNO>NCT00429962</DOCNO>
	<brief_summary>This pilot study design evaluate safety efficacy intravitreal ranibizumab use combination verteporfin photodynamic therapy ( Visudyne速 ) compare ranibizumab monotherapy treatment subfoveal CNV secondary AMD</brief_summary>
	<brief_title>Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy Subfoveal CNV</brief_title>
	<detailed_description>Intravitreal ranibizumab show increase average vision patient subfoveal CNV secondary AMD . However , treatment provide benefit patient treatment regimen require monthly intravitreal injection . Ranibizumab anti-VEGF-A monoclonal antibody fragment . Verteporfin photodynamic therapy act occlude newly form vessel . The combination therapy act different mode action bear potential provide convenient le frequent therapy maintaining/improving increase vision improvement observe ranibizumab monotherapy . The strategic goal evaluate whether intravitreal ranibizumab combination verteporfin photodynamic therapy effective , safe convenient treatment patient subfoveal CNV secondary AMD explore potential advantage treatment compare ranibizumab monotherapy</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>1. patient 50 year , subfoveal CNV type secondary agerelated macular degeneration ( AMD ) , `` maculatreatment last 30 day ( e.g . PDT , TA , Laser , Macugen速 ) . area CNV must occupy least &gt; 50 % lesion ( total lesion size 5400 micron great linear dimension ) Occult CNV : recent disease progression bleed VA decrease last three month &gt; 5 letter 2 two line ( Snellen ) 10 % increase lesion size last three month 2 . Best correct visual acuity score 2473 letter ( 20/40 20/320 ) ( ETDRS 4 ) 1 . Prior treatment mit Laser , PDT , Macugen , TA 2 . Prior treatment radiatio , vitrectomy , transpupillary thermotherapy 3 . History surgical intervention study eye within two month precede day 1 4. concurrent use systemic antiVEGF agent 5. previous treatment participation clinical trial involve antiangiogenic drug ( Pegaptanib , ranibizumab , anecortave acetate corticosteroid ) . 6 . Ocular disorder study eye may confound interpretation study result , include retinal detachment macular hole ( Stage 3 4 ) , active intraocular inflammation ( grade trace ) persistent macular edema due uveitis inflammatory diseases 7 . Retinal pigment epithelium tear , vitreous hemorrhage history rhegmatogenous retinal detachment macular hole study eye 8 . History idiopathic autoimmuneassociated uveitis either eye , active infectious conjunctivitis , keratitis , scleritis endophthalmitis either eye 9 . Extracapsular extraction cataract phacoemulsification within two month precede day 1 , history postoperative complication within last 12 month precede day 1 history postoperative complication within last 12 month precede day 1 study eye ( uveitis , cyclitis , iritis etc . ) 10 . Glaucoma IOP &gt; 25 mmHg despite therapy 11 . Aphakia absence posterior capsule study eye 12 . Spherical equivalent &gt; 8</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>subfoveal choroidal neovascularization ( CNV )</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>ranibizumab monotherapy</keyword>
	<keyword>combine verteporfin-therapy</keyword>
	<keyword>Lucentis速 ( ranibizumab )</keyword>
	<keyword>Visudyne速</keyword>
	<keyword>photodynamic therapy</keyword>
</DOC>